Diclofenac
Other / unclassified targets KMO, MYC, PPARG via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ZIPSOR | — | 2021-05-25 | fda.gov ↗ |
| Label expansion | US (FDA) | VOLTAREN ARTHRITIS PAIN | — | 2020-02-14 | fda.gov ↗ |
| Label expansion | US (FDA) | ZORVOLEX | — | 2014-08-22 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | VOLTAREN | — | 1996-07-23 – 1998-02-25 | fda.gov ↗ |
| Approved | US (FDA) | VOLTAREN | — | 1988-07-28 | fda.gov ↗ |
Trials 224 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT06500871 | Aug 2024 → May 2025 overdue | pulpitis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06053411 | Mar 2024 → Aug 2026 overdue | — | Washington State University | Recruiting | No outcome recorded |
| Phase 0 | NCT05413096 | Jun 2021 → Oct 2022 | aphthous stomatitis | Al-Azhar University | Completed | No outcome recorded |
| Phase 0 | NCT03145259 | Apr 2017 → Aug 2019 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 0 | NCT02485145 | Jul → Dec 2015 | osteoarthritis, hand | Transdermal Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 0 | NCT01592019 | Apr → Nov 2012 | — | University of Florida | Completed | No outcome recorded |
| Phase 133 trials | ||||||
| Phase 1 | NCT06510062 | Jul → Sep 2024 | — | ZetrOZ, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05968482 | Jul → Dec 2023 | — | Amzell | Completed | No outcome recorded |
| Phase 1 | NCT05752526 | May → Oct 2023 | primary dysmenorrhea | Daré Bioscience, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05254574 | Feb 2022 → May 2026 overdue | osteoarthritis | ZetrOZ, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04882319 | Jun 2021 → Mar 2022 | osteoarthritis, knee | Noven Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04900129 | Dec 2020 | COVID-19 | Sher-E-Bangla Medical College | Completed | No outcome recorded |
| Phase 1 | NCT04391842 | Sep → Dec 2019 | osteoarthritis, knee | ZetrOZ, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04235426 | Jan 2018 → Jan 2021 | carpal tunnel syndrome | Dalia Salah Saif | Unknown | No outcome recorded |
| Phase 1 | NCT04585321 | Nov 2017 → May 2018 | — | Fidia Farmaceutici s.p.a. | Completed | No outcome recorded |
| Phase 1 | NCT03074162 | Apr → Jun 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03072485 | Mar 2017 → Feb 2019 | — | Anne Chang | Completed | No outcome recorded |
| Phase 1 | NCT02714842 | Mar → May 2016 | — | BDD Pharma Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03766984 | Jun 2015 | — | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02495831 | May 2015 | — | Zambon SpA | Completed | No outcome recorded |
| Phase 1 | NCT02666846 | Mar → May 2015 | — | Futura Medical Developments Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02361619 | Feb 2015 → Sep 2016 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02201238 | Oct → Nov 2014 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02169154 | Jun → Jul 2014 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02192203 | Apr → Jul 2014 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02004301 | Jan → Mar 2014 | — | BDD Pharma Ltd | Completed | No outcome recorded |
| Phase 1 | NCT01876615 | Jul → Oct 2013 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01742663 | Oct 2012 → Jul 2013 | actinic keratosis | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01596647 | May 2012 → Jul 2014 | neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01202799 | Sep → Nov 2010 | — | Mallinckrodt | Completed | No outcome recorded |
| Phase 1 | NCT01812538 | May → Jul 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00805090 | Dec 2008 → Mar 2009 | chronic kidney disease, liver disorder | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00548678 | Oct → Nov 2007 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00509743 | Sep 2007 → Feb 2008 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT02171507 | May → Jul 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT00913887 | Apr → May 1994 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00914160 | Aug → Sep 1993 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00913224 | Apr 1993 | — | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00893854 | — | cystoid macular edema, uveitis | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06439251 | Oct 2023 → Jun 2025 | patellofemoral pain syndrome | University of Lahore | Completed | No outcome recorded |
| Phase 1/2 | NCT03519152 | Mar 2016 → May 2017 | chronic periodontitis | Tatyasaheb Kore Dental College | Completed | No outcome recorded |
| Phase 222 trials | ||||||
| Phase 2 | NCT06731270 | Apr 2025 → Jan 2027 expected | non-small cell lung carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT06184685 | Oct → Nov 2021 | osteoarthritis, knee | Thammasat University | Completed | No outcome recorded |
| Phase 2 | NCT04341402 | May 2020 → Mar 2021 | tinea unguium | William N Handelman | Unknown | No outcome recorded |
| Phase 2 | NCT03949673 | Apr 2019 → Aug 2020 | osteoarthritis, hip, osteoarthritis, knee | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04591795 | Jan 2018 → Oct 2020 | osteoarthritis | Mr NARIN KAKATUM | Unknown | No outcome recorded |
| Phase 2 | NCT03277066 | Sep 2017 → Sep 2019 | osteoarthritis, knee | Noven Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03825016 | Aug 2017 → Jan 2020 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT03090971 | Feb → Mar 2017 | neurofibroma, neurofibromatosis type 1 | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase 2 | NCT02424578 | May 2015 → Apr 2016 | — | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT02598102 | Apr → Aug 2015 | — | Institute of Nephro Urology, Bangalore | Completed | No outcome recorded |
| Phase 2 | NCT01812928 | Mar → Aug 2013 | — | Aga Khan University | Completed | No outcome recorded |
| Phase 2 | NCT01706588 | Jan → May 2013 | — | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 2 | NCT02417337 | Aug 2012 → Aug 2014 | pulpitis | University of Khartoum | Completed | No outcome recorded |
| Phase 2 | NCT01939743 | Oct 2011 → Sep 2012 | prostate carcinoma | Aga Khan University | Completed | No outcome recorded |
| Phase 2 | NCT01119898 | Aug 2010 → Feb 2011 | osteoarthritis, knee | Mallinckrodt | Completed | No outcome recorded |
| Phase 2 | NCT00985439 | Sep → Dec 2009 | — | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00991861 | Aug 2009 → Feb 2010 | actinic keratosis | Almirall, S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00484120 | Jun 2007 → Nov 2008 | osteoarthritis, knee | Pharmos | Completed | No outcome recorded |
| Phase 2 | NCT00601640 | Jan 2007 → Feb 2010 | benign neoplasm of skin | University of Arizona | Completed | No outcome recorded |
| Phase 2 | NCT00371696 | Dec 2001 → Dec 2003 | osteoarthritis | University of Bristol | Completed | No outcome recorded |
| Phase 2 | NCT02658799 | Jan 2000 → Dec 2004 | poisoning | Baskent University | Completed | No outcome recorded |
| Phase 2 | NCT00242489 | Jun 1998 → Feb 1999 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT06207253 | Nov → Dec 2025 overdue | dental pulp disorder | British University In Egypt | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03341260 | Dec 2016 → Feb 2018 | pulpitis | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT03174860 | Oct 2016 → Feb 2018 | pulpitis | Cairo University | Completed | No outcome recorded |
| Phase 2/3 | NCT02714699 | Oct 2016 → Mar 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03163420 | Jul 2016 → Jul 2017 | pulpitis | Cairo University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00276419 | Jun 2005 → May 2009 | breast disorder | Mayo Clinic | Terminated | No outcome recorded |
| Phase 360 trials | ||||||
| Phase 3 | NCT07145645 | Apr 2026 → Sep 2027 expected | musculoskeletal system disorder | University of Calgary | Recruiting | No outcome recorded |
| Phase 3 | NCT06693648 | Feb → Dec 2025 | osteoarthritis, knee | Amzell | Completed | No outcome recorded |
| Phase 3 | NCT06731556 | Dec 2024 | — | Bezmialem Vakif University | Completed | No outcome recorded |
| Phase 3 | NCT06561035 | Sep 2024 → Aug 2025 overdue | — | Campbell Clinic | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05312645 | Dec 2023 → Aug 2024 | headache disorder | Loma Linda University | Withdrawn | No outcome recorded |
| Phase 3 | NCT05171673 | Oct 2021 → Jun 2024 | — | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 3 | NCT05626140 | Sep 2021 → May 2022 | sciatica | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04683627 | Dec 2020 → Jul 2022 | osteoarthritis, knee | Noven Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03597867 | Apr → Jul 2018 | — | University of Trieste | Completed | No outcome recorded |
| Phase 3 | NCT03826550 | Jan → Jun 2018 | actinic keratosis | Encube Ethicals Pvt. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03714672 | Aug 2017 → Mar 2018 | — | Grünenthal GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02700815 | May 2016 → Jul 2017 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 3 | NCT02709590 | Mar → Jun 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02596451 | Aug 2015 → Mar 2016 | osteoarthritis, knee | Glenmark Pharmaceuticals Ltd. India | Completed | No outcome recorded |
| Phase 3 | NCT02476422 | Apr → Aug 2015 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02752971 | Feb 2015 → Feb 2016 | — | Hospital Central Dr. Luis Ortega | Completed | No outcome recorded |
| Phase 3 | NCT02339428 | Jan 2015 → Oct 2016 | anemia | University Hospital Rijeka | Completed | No outcome recorded |
| Phase 3 | NCT02271854 | Oct → Dec 2014 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT02121002 | Apr → Oct 2014 | osteoarthritis | Amneal Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02194088 | Apr → Nov 2014 | — | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02068859 | Jan 2014 → Jan 2015 | chronic pain syndrome | FPR Specialty Pharmacy | Unknown | No outcome recorded |
| Phase 3 | NCT02100670 | Nov 2013 → Mar 2015 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01967550 | Oct 2013 → May 2014 | osteoarthritis, knee | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01962987 | Mar → Sep 2013 | actinic keratosis | Actavis Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01421433 | May → Aug 2012 | — | Farmoquimica S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT01511939 | Feb 2012 → May 2013 | blood coagulation disease, osteoarthritis, knee | Nathan Wei, MD, FACP, FACR | Completed | No outcome recorded |
| Phase 3 | NCT01510912 | Jan 2012 → Mar 2013 | osteoarthritis | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01462435 | Oct 2011 → Feb 2012 | — | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01461369 | Oct 2011 → Mar 2012 | osteoarthritis | Iroko Pharmaceuticals, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01456611 | Sep 2011 → Apr 2012 | osteoarthritis, knee | Anchen Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 3 | NCT01300312 | Feb → Jun 2011 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01272947 | Jan → Jul 2011 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01272934 | Jan → Aug 2011 | tenosynovitis of foot and ankle | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01255423 | Nov 2010 → Jun 2011 | — | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01265602 | Nov 2010 → Mar 2012 | actinic keratosis | Almirall, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT00943098 | Sep 2009 → Mar 2010 | — | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 3 | NCT00931866 | Apr → Sep 2009 | — | Cerimon Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00869180 | Feb → Jun 2009 | — | Cerimon Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00869063 | Feb → Jul 2009 | — | Cerimon Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00726388 | Sep 2008 → May 2009 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00546832 | Oct 2007 → Oct 2008 | osteoarthritis, knee | Mika Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00507026 | Jul 2007 → Oct 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00426621 | Nov 2006 → Jun 2007 | osteoarthritis, knee | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00441051 | Nov → Dec 2006 | sunburn | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00375934 | Sep 2006 → Jan 2007 | neuropathy, painful | Xanodyne Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00366444 | Aug → Oct 2006 | neuropathy, painful | Xanodyne Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00448110 | May 2006 → Nov 2007 | neuropathy, painful | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00171652 | May → Oct 2005 | osteoarthritis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00171665 | May → Dec 2005 | osteoarthritis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00171678 | Oct 2004 → Aug 2005 | osteoarthritis, knee | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00171691 | Oct 2004 → Jun 2006 | osteoarthritis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00171626 | Aug 2004 → Jun 2005 | osteoarthritis, knee | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00108992 | Feb 2004 → Sep 2005 | osteoarthritis, knee | Nuvo Research Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00092378 | Sep → Dec 2003 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00140933 | Apr 2003 → ? | — | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00092742 | Feb 2003 → Dec 2005 | rheumatoid arthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00250445 | Jan 2003 → May 2006 | arthritic joint disease | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00092703 | Jun 2002 → Nov 2003 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT00139646 | Apr 2002 → Apr 2004 | — | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00542087 | Mar → Dec 2002 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 453 trials | ||||||
| Phase 4 | NCT07565012 | Oct 2025 → Mar 2026 | periapical periodontitis, pulpitis | Armed Forces Institute of Dentistry, Pakistan | Completed | No outcome recorded |
| Phase 4 | NCT07379762 | Feb → Jul 2025 | — | CMH Multan Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT06379893 | Apr → Oct 2024 | — | HALEON | Completed | No outcome recorded |
| Phase 4 | NCT05761015 | Dec 2023 → Apr 2028 expected | chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee | University Hospital, Clermont-Ferrand | Recruiting | No outcome recorded |
| Phase 4 | NCT05211154 | May 2022 → Apr 2025 | migraine with aura, migraine without aura | Danish Headache Center | Terminated | No outcome recorded |
| Phase 4 | NCT06231043 | Apr 2022 → Mar 2023 | — | Lampang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05188131 | Oct → Dec 2021 | hypopituitarism | A.O.U. Città della Salute e della Scienza | Completed | No outcome recorded |
| Phase 4 | NCT04585438 | Sep 2021 → Sep 2022 | pulpitis | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT05488925 | Jun 2021 → Feb 2022 | pulpitis | Farjad Zafar | Completed | No outcome recorded |
| Phase 4 | NCT04611529 | Mar 2021 → Jun 2023 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04608981 | Mar → Dec 2021 | pulpitis | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT07696104 | Oct 2020 → May 2024 | cystoid macular edema | Pomeranian Medical University Szczecin | Completed | No outcome recorded |
| Phase 4 | NCT05433428 | Aug 2020 → Jan 2023 | cataract, dry eye syndrome | Ifocus Oyeklinikk | Unknown | No outcome recorded |
| Phase 4 | NCT04054830 | Aug 2019 → Jun 2022 | glaucoma | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 4 | NCT03861611 | Jul 2019 → Feb 2021 | — | Montefiore Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03781544 | Jan 2019 → Jul 2025 | osteoarthritis | University of Zurich | Unknown | No outcome recorded |
| Phase 4 | NCT04050644 | Oct 2018 → Jun 2024 | senile cataract | Universitaire Ziekenhuizen KU Leuven | Unknown | No outcome recorded |
| Phase 4 | NCT03605914 | Aug 2018 → Jul 2020 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT03472339 | Jan → Apr 2018 | — | Hamad Medical Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT03745599 | Nov 2017 → Sep 2018 | — | Near East University, Turkey | Completed | No outcome recorded |
| Phase 4 | NCT02826031 | Apr 2016 → Oct 2017 | osteoarthritis, knee | Kunming Baker Norton Pharmaceutical Sales Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02714231 | Mar 2016 → Feb 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT03221946 | Jan 2016 → Sep 2017 | — | Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT02664116 | Jan 2016 → Jul 2017 | migraine disorder | Scripps Health | Unknown | No outcome recorded |
| Phase 4 | NCT02287376 | Jan 2015 → Feb 2016 | migraine disorder | Depomed | Completed | No outcome recorded |
| Phase 4 | NCT02547896 | Sep 2014 → Jun 2015 | impacted teeth, multiple | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02287350 | Sep 2014 → Jan 2016 | — | Depomed | Completed | No outcome recorded |
| Phase 4 | NCT02187614 | Aug 2014 → Feb 2015 | urolithiasis | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02132247 | May 2014 → Oct 2016 | — | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 4 | NCT02445599 | Apr 2014 → Apr 2016 | lung disorder | University of Debrecen | Completed | No outcome recorded |
| Phase 4 | NCT01982539 | Nov 2013 → May 2014 | — | Depomed | Completed | No outcome recorded |
| Phase 4 | NCT01935531 | Jun 2013 → Jan 2016 | actinic keratosis | University Hospital Regensburg | Completed | No outcome recorded |
| Phase 4 | NCT02253446 | May 2013 → Jul 2014 | primary dysmenorrhea | Pamukkale University | Completed | No outcome recorded |
| Phase 4 | NCT01907984 | Dec 2012 → Apr 2013 | — | University of Debrecen | Completed | No outcome recorded |
| Phase 4 | NCT01666197 | Aug 2012 → Jan 2013 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01039545 | Feb 2012 → Dec 2014 | urinary tract infection | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| Phase 4 | NCT02779530 | Oct 2011 → Jul 2013 | drug-induced mental disorder | Eduardo Barbosa Coelho | Completed | No outcome recorded |
| Phase 4 | NCT01383954 | Jun 2011 → Aug 2012 | osteoarthritis, knee | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01335724 | Apr → Jul 2011 | — | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT01257126 | Apr → Dec 2011 | respiratory tract infectious disorder | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT02961855 | Jan 2011 → Jan 2013 | anal fistula, hemorrhoid | Hospital de Viladecans | Completed | No outcome recorded |
| Phase 4 | NCT01454791 | Jan 2011 → Mar 2013 | multiple sclerosis | Brown, Theodore R., M.D., MPH | Completed | No outcome recorded |
| Phase 4 | NCT01211431 | Sep 2010 → Oct 2012 | — | Nîmes University Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT01019980 | Mar 2010 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT01054820 | Jan → Mar 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00792376 | Aug 2009 → Dec 2011 | disease of the tendon | Argentine Tennis Association | Completed | No outcome recorded |
| Phase 4 | NCT00491192 | Jun 2007 → Jun 2009 | subarachnoid hemorrhage, traumatic brain injury | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Unknown | No outcome recorded |
| Phase 4 | NCT00140972 | Dec 2004 → Jun 2005 | osteoarthritis | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00090181 | Jun 2004 → Mar 2005 | chronic pain syndrome | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT00140920 | May → Sep 2004 | — | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 4 | NCT00174317 | Aug 2003 → Feb 2005 | osteoarthritis, hip | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00377806 | Jan 2003 → Sep 2006 | thrombophlebitis | Novartis | Completed | No outcome recorded |
| Phase 4 | NCT02181920 | Mar → Nov 2000 | — | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase not applicable41 trials | ||||||
| — | NCT07101016 | Aug 2025 overdue | periapical periodontitis | Mariam Hesham Mahmoud Abdelfattah Eissa | Not yet recruiting | No outcome recorded |
| — | NCT07646093 | May 2025 | — | Hospital Universitario de Caracas | Completed | No outcome recorded |
| — | NCT06954181 | Mar → Apr 2025 | — | HALEON | Completed | No outcome recorded |
| — | NCT06905561 | Feb 2025 → Jun 2026 overdue | breast cancer, head and neck neoplasm | The Second Affiliated Hospital of Hainan Medical University | Recruiting | No outcome recorded |
| — | NCT06574191 | Jan 2025 → Jan 2028 expected | osteoarthritis, knee | University of California, Davis | Recruiting | No outcome recorded |
| — | NCT07203651 | Jan → Jun 2025 overdue | — | Pakistan Institute of Medical Sciences | Active not recruiting | No outcome recorded |
| — | NCT06453291 | Jul 2024 → Apr 2025 overdue | chronic pain syndrome | Iffat Anwar Medical Complex | Recruiting | No outcome recorded |
| — | NCT06937853 | May 2024 → Jul 2025 overdue | — | Ataturk University | Recruiting | No outcome recorded |
| — | NCT06632015 | Jan → May 2024 | acute apical periodontitis | Mustafa Kemal University | Completed | No outcome recorded |
| — | NCT06307106 | Jan → Oct 2024 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT06186921 | Dec 2023 → Mar 2024 | pulpitis | Jamia Millia Islamia | Unknown | No outcome recorded |
| — | NCT05947461 | Jun 2023 → Jun 2024 | acute pancreatitis | Air Force Military Medical University, China | Terminated | No outcome recorded |
| — | NCT06710600 | Sep 2022 → Apr 2024 | photosensitivity disease | Medical University of Vienna | Completed | No outcome recorded |
| — | NCT07267182 | Aug 2022 → Feb 2023 | — | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT05322603 | Mar → Aug 2022 | — | Petrovsky National Research Centre of Surgery | Completed | No outcome recorded |
| — | NCT06845930 | Apr → Sep 2021 | — | Assumpta Nnenna Nweke | Completed | No outcome recorded |
| — | NCT04593160 | Jan → Dec 2021 | pulpitis | Cairo University | Unknown | No outcome recorded |
| — | NCT04622488 | Nov 2020 → Jul 2022 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04592016 | Oct 2020 → Aug 2021 | — | Joanneum Research Forschungsgesellschaft mbH | Completed | No outcome recorded |
| — | NCT04511832 | Mar 2018 → Dec 2021 | breast cancer | China Medical University Hospital | Completed | No outcome recorded |
| — | NCT03409874 | Feb 2018 → Jul 2020 | temporomandibular joint dysfunction syndrome | Alabama Physical Therapy & Acupuncture | Completed | No outcome recorded |
| — | NCT03518463 | Jun → Jul 2017 | pregnancy disorder | Mbarara University of Science and Technology | Completed | No outcome recorded |
| — | NCT03116672 | Feb 2016 → Feb 2017 | pulpitis | Universidad Autonoma de Baja California | Completed | No outcome recorded |
| — | NCT03269591 | Feb → Sep 2016 | primary dysmenorrhea | Cairo University | Completed | No outcome recorded |
| — | NCT02665533 | Jan 2016 | — | Federal University of the Valleys of Jequitinhonha and Mucuri | Completed | No outcome recorded |
| — | NCT02506348 | Jul 2015 → Jan 2016 | — | Wolfson Medical Center | Unknown | No outcome recorded |
| — | NCT02440399 | Jul 2015 → May 2017 | — | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT02059018 | Feb 2014 → Feb 2015 | retinal ischemia | University of Aarhus | Completed | No outcome recorded |
| — | NCT01764048 | Nov 2012 → Jan 2014 | — | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| — | NCT01762306 | Nov 2012 → Jun 2013 | — | Mahidol University | Unknown | No outcome recorded |
| — | NCT01694212 | Oct 2012 → Oct 2016 | cataract, diabetic retinopathy, macular retinal edema | Eye Clinic Medic Zuljan Jukic | Completed | No outcome recorded |
| — | NCT01717599 | Aug 2012 → Aug 2013 | pancreatitis | Yonsei University | Completed | No outcome recorded |
| — | NCT02087462 | Jan 2012 → Apr 2014 | intervertebral disk degenerative disorder | Chengdu University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01246180 | Oct → Dec 2010 | — | Hospices Civils de Lyon | Completed | No outcome recorded |
| — | NCT00530387 | Jul 2008 → Jul 2011 | photoallergic dermatitis | NHS Tayside | Completed | No outcome recorded |
| — | NCT01009021 | Mar 2008 → Mar 2009 | — | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT00536068 | Aug 2006 → Aug 2007 | vascular hemostatic disease | Kantonsspital Graubünden | Completed | No outcome recorded |
| — | NCT00471393 | May 2006 → Apr 2007 | osteoarthritis | University of Alberta | Completed | No outcome recorded |
| — | NCT00476593 | Sep 2005 → Dec 2009 | iridocyclitis, macular retinal edema | Norwegian University of Science and Technology | Completed | No outcome recorded |
| — | NCT00221052 | Jun → Jul 2005 | obesity disorder | TNO | Completed | No outcome recorded |
| — | NCT00226538 | Aug 1999 → ? | — | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01579890 | — | osteoarthritis, hand | Mallinckrodt | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 211 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06029296 Comparator | Jul 2024 → Aug 2026 overdue | alcohol-related disorders | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
| Phase 0 | NCT07016451 Background | Apr 2024 → Sep 2025 | radiation cystitis | Ramathibodi Hospital | Completed | No outcome recorded |
| Phase 0 | NCT05582421 Comparator | Dec 2022 → Oct 2023 | dental pulp necrosis, periapical periodontitis | Cairo University | Unknown | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT06752486 Comparator | Dec 2024 → May 2025 overdue | — | Research Institute of Ophthalmology, Egypt | Recruiting | No outcome recorded |
| Phase 1 | NCT06636227 Comparator | Dec 2024 → May 2026 overdue | alcohol dependence | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 1 | NCT06729073 Comparator | Nov 2024 → Jun 2025 | — | Amzell | Completed | No outcome recorded |
| Phase 1 | NCT05883241 Background | Jun 2023 → Feb 2026 overdue | disease of bone structure | ZetrOZ, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04330547 Comparator | Feb 2018 → Feb 2019 | akinetic mutism, brain injury | University of Liege | Completed | No outcome recorded |
| Phase 1 | NCT01946984 Comparator | Jun 2012 → Jun 2013 | acute pancreatitis | Specialized Arab Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00999791 Comparator | Jul 2009 → ? | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1 | NCT00474136 Comparator | Mar → May 2007 | — | Javelin Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06158620 Comparator | Mar 2025 → Apr 2027 expected | ureterolithiasis, urolithiasis | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06829030 Comparator | Jul 2024 → Feb 2025 overdue | — | Aksaray University Training and Research Hospital | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06252441 Comparator | Mar 2024 → May 2025 | pancreatitis | Tanta University | Completed | No outcome recorded |
| Phase 1/2 | NCT05050448 Comparator | Aug 2021 → Dec 2022 | osteoarthritis, knee | ZetrOZ, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01413854 Comparator | Aug 2011 | — | Region Skane | Withdrawn | No outcome recorded |
| Phase 224 trials | ||||||
| Phase 2 | NCT07663825 Background | Sep 2026 → Sep 2030 expected | congenital vascular malformation | University Hospital, Tours | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06257537 Comparator | Oct 2024 → Jun 2026 | osteoarthritis, knee | ZetrOZ, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05882812 Comparator | Jun → Dec 2023 | osteoarthritis, knee | ZetrOZ, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05641246 Comparator | Dec 2022 → Nov 2023 | hand-foot syndrome | German University in Cairo | Completed | No outcome recorded |
| Phase 2 | NCT05653401 Comparator | Nov 2022 → Aug 2023 | urinary tract obstruction | University of Monastir | Completed | No outcome recorded |
| Phase 2 | NCT05026320 Comparator | Aug → Dec 2021 | — | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT04091022 Comparator | Jan 2021 → Dec 2025 | skin cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03471507 Comparator | Dec 2020 → Sep 2022 | chronic pain syndrome, musculoskeletal system disorder | Winston Parris, MD | Completed | No outcome recorded |
| Phase 2 | NCT04511195 Comparator | Jul 2020 → Jan 2021 | osteoarthritis, knee | Coordinación de Investigación en Salud, Mexico | Unknown | No outcome recorded |
| Phase 2 | NCT04849468 Comparator | Jun 2019 → Oct 2021 | — | Imam Abdulrahman Bin Faisal University | Unknown | No outcome recorded |
| Phase 2 | NCT04110119 Background | Oct 2018 → Nov 2019 | — | Medipol University | Completed | No outcome recorded |
| Phase 2 | NCT04067492 Comparator | Mar 2018 → Mar 2020 | gout | R-Pharm | Terminated | No outcome recorded |
| Phase 2 | NCT02636569 Comparator | Oct 2017 → Dec 2025 | skin cancer | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT03199924 Comparator | Jul 2016 → Jan 2022 | urinary tract obstruction | University of Monastir | Completed | No outcome recorded |
| Phase 2 | NCT03041779 Comparator | Oct 2015 → Jul 2016 | — | Clinical Research Centre, Malaysia | Completed | No outcome recorded |
| Phase 2 | NCT02332057 Comparator | Feb → Sep 2015 | — | Cairo University | Completed | No outcome recorded |
| Phase 2 | NCT02286453 Comparator | Sep 2014 → Sep 2015 | osteoarthritis, knee | Thammasat University | Completed | No outcome recorded |
| Phase 2 | NCT02306031 Comparator | Jun 2013 → Jun 2014 | diabetic retinopathy | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT01481610 Comparator | Jan → Nov 2012 | arthropathy, chronic renal failure syndrome | Hospital Central Sur de Pemex | Terminated | No outcome recorded |
| Phase 2 | NCT01358045 Comparator | Nov 2011 → Feb 2013 | basal cell carcinoma | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01205477 Background | Sep 2009 → Jul 2010 | bursitis | Autonomous University of Nuevo León | Completed | No outcome recorded |
| Phase 2 | NCT00523120 Comparator | Sep 2008 → Dec 2011 | otitis externa | Sieff Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT00264147 Comparator | Jan 2006 → Mar 2008 | rheumatoid arthritis | Organon and Co | Completed | No outcome recorded |
| Phase 2 | NCT02088411 Comparator | Nov 2000 → Nov 2001 | osteoarthritis | Atrium Innovations | Completed | No outcome recorded |
| Phase 2/310 trials | ||||||
| Phase 2/3 | NCT03595150 Comparator | Jan 2026 → Dec 2027 expected | common bile duct disorder | Karolinska Institutet | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05871086 Background | May → Dec 2023 | juvenile idiopathic arthritis | Nourhan Elsherif | Unknown | No outcome recorded |
| Phase 2/3 | NCT03691844 Comparator | Oct 2018 → Jul 2019 | osteoarthritis, knee | Amzell | Completed | No outcome recorded |
| Phase 2/3 | NCT03178539 Comparator | Jan 2017 → Dec 2018 | — | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT03380533 Comparator | Sep 2016 → Dec 2017 | rotator cuff syndrome | Hospital Italiano de Buenos Aires | Completed | No outcome recorded |
| Phase 2/3 | NCT02255045 Comparator | Jun 2014 → Feb 2016 | primary dysmenorrhea | Laboratorios Andromaco S.A. | Completed | No outcome recorded |
| Phase 2/3 | NCT02193620 Background | Apr 2013 → Sep 2014 | — | PhytoHealth Corporation | Completed | No outcome recorded |
| Phase 2/3 | NCT01590342 Comparator | May 2012 → Jan 2017 | pulmonary embolism | Ministry of Health, Spain | Terminated | No outcome recorded |
| Phase 2/3 | NCT00640705 Comparator | Jan → Jul 2008 | — | Cerimon Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2/3 | NCT00640939 Comparator | Dec 2007 → Apr 2008 | bicipital tenosynovitis, de Quervain disease, epicondylitis, rotator cuff syndrome +1 | Cerimon Pharmaceuticals | Completed | No outcome recorded |
| Phase 331 trials | ||||||
| Phase 3 | NCT07475663 Comparator | Nov 2025 → Feb 2026 | epicondylitis, osteoarthritis, knee, patellofemoral pain syndrome, tenosynovitis of foot and ankle | Taisho Pharmaceutical Indonesia | Completed | No outcome recorded |
| Phase 3 | NCT07304882 Background | Nov 2023 → Jan 2025 | impacted teeth, multiple | University of Science and Technology, Yemen | Completed | No outcome recorded |
| Phase 3 | NCT06594822 Comparator | Aug 2023 → Jan 2024 | rheumatoid arthritis | King Edward Medical University | Completed | No outcome recorded |
| Phase 3 | NCT05816226 Comparator | Jun 2023 → Jan 2026 overdue | temporomandibular joint disorder | University of the Pacific | Recruiting | No outcome recorded |
| Phase 3 | NCT02985671 Comparator | Jan → Sep 2021 | — | Ache Laboratorios Farmaceuticos S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT04552327 Comparator | Oct 2020 → Jan 2023 | actinic keratosis | Infectopharm Arzneimittel GmbH | Completed | No outcome recorded |
| Phase 3 | NCT04421911 Comparator | Mar → Sep 2020 | osteoarthritis | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04976088 Comparator | May → Oct 2018 | — | Fidia Farmaceutici s.p.a. | Completed | No outcome recorded |
| Phase 3 | NCT06192420 Comparator | Feb 2018 → Nov 2020 | — | Biologische Heilmittel Heel GmbH | Completed | No outcome recorded |
| Phase 3 | NCT03031938 Background | Nov 2017 → Jun 2020 | osteoarthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02952898 Comparator | Oct 2016 → Jul 2017 | actinic keratosis | Balmoral Medical company | Completed | No outcome recorded |
| Phase 3 | NCT02674386 Background | Aug 2016 → Jul 2019 | osteoarthritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02769572 Comparator | May 2016 → Jun 2019 | osteoarthritis, knee | Chengdu University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02760888 Comparator | May → Jun 2016 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT02611804 Comparator | Oct 2015 → Aug 2016 | actinic keratosis | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 3 | NCT02528188 Comparator | Jul 2015 → Oct 2018 | chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02433418 Comparator | May 2015 → Dec 2017 | female infertility | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02508805 Background | May → Sep 2015 | radiculopathy | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02419651 Comparator | Apr 2015 → Dec 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02428777 Comparator | Apr 2015 → Dec 2019 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02425709 Comparator | Apr 2015 → Dec 2017 | — | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT02658721 Background | Jan → Jun 2013 | — | Bagcilar Training and Research Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01542567 Comparator | May 2012 → May 2014 | urinary bladder cancer | Carmel Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT01761071 Comparator | Jan → Nov 2012 | — | Yonsei University | Completed | No outcome recorded |
| Phase 3 | NCT01229774 Comparator | Feb 2011 → Aug 2014 | osteoarthritis, hip | University of Regensburg | Completed | No outcome recorded |
| Phase 3 | NCT00942448 Comparator | Sep 2009 → Jan 2010 | — | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 3 | NCT00864097 Comparator | Aug 2009 → Nov 2010 | osteoarthritis | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT01066520 Comparator | Aug 2009 → Sep 2011 | — | Biologische Heilmittel Heel GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01858090 Comparator | Jan → Oct 2009 | — | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT00594854 Comparator | Sep 2007 → Sep 2008 | gastric ulcer | POZEN | Terminated | No outcome recorded |
| Phase 3 | NCT00648141 Comparator | Jan 2003 → Jan 2005 | ankylosing spondylitis | Pfizer | Completed | No outcome recorded |
| Phase 461 trials | ||||||
| Phase 4 | NCT07506265 Comparator | May → Dec 2025 | pulpitis | Fayoum University | Completed | No outcome recorded |
| Phase 4 | NCT06918340 Comparator | Nov → Dec 2024 overdue | — | Haydarpasa Numune Training and Research Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07088042 Comparator | Sep 2024 → Feb 2025 | pulpitis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT06373978 Comparator | Aug 2024 → Jun 2026 overdue | chronic pain syndrome | The Cleveland Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06012097 Comparator | Jun 2024 → Apr 2026 overdue | de Quervain disease | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| Phase 4 | NCT07610265 Comparator | Apr 2024 → Oct 2025 | — | Nims University Rajasthan | Completed | No outcome recorded |
| Phase 4 | NCT06146491 Comparator | Aug 2023 → Jan 2024 | — | B.P. Koirala Institute of Health Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT05387525 Comparator | Oct 2022 → Jul 2027 expected | actinic keratosis | Almirall, S.A. | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04199572 Background | Oct 2022 → Feb 2023 | musculoskeletal system disorder | Hamad Medical Corporation | Completed | No outcome recorded |
| Phase 4 | NCT06111573 Comparator | Jun 2022 → Jan 2023 | temporomandibular joint dysfunction syndrome | Yuzuncu Yil University | Completed | No outcome recorded |
| Phase 4 | NCT05121233 Comparator | Nov 2021 → Oct 2022 | lung neoplasm, pleural empyema, pleural neoplasm, pneumothorax | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT04766996 Background | May → Dec 2021 | substance-related disorder | Emory University | Terminated | No outcome recorded |
| Phase 4 | NCT04657952 Comparator | Dec 2020 → May 2021 | intracranial hypotension | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT04148729 Comparator | May 2019 → Nov 2020 | — | Cukurova University | Completed | No outcome recorded |
| Phase 4 | NCT03910088 Comparator | Apr → Jun 2019 | intracranial hypotension | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT04585334 Comparator | Mar 2019 → Dec 2024 | — | Fidia Farmaceutici s.p.a. | Unknown | No outcome recorded |
| Phase 4 | NCT03831321 Comparator | Dec 2018 → Apr 2019 | benign prostatic hyperplasia, urinary bladder cancer | Taha Uçar | Unknown | No outcome recorded |
| Phase 4 | NCT03529097 Comparator | Jun 2018 → Dec 2019 | urinary tract obstruction | Sheba Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03493490 Comparator | Mar 2018 → May 2019 | neuropathy, painful | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT03473665 Comparator | Mar 2018 → Aug 2019 | ankylosing spondylitis | Columbia University | Terminated | No outcome recorded |
| Phase 4 | NCT03506763 Comparator | Aug 2017 → Dec 2018 | — | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 4 | NCT03939884 Comparator | Mar 2017 → Feb 2018 | — | University of Toronto | Completed | No outcome recorded |
| Phase 4 | NCT03039426 Comparator | Jan → Jun 2017 | — | Department of Medical Services Ministry of Public Health of Thailand | Completed | No outcome recorded |
| Phase 4 | NCT06105827 Background | Oct 2016 → Apr 2019 | ureterolithiasis | Xintian Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT02918812 Comparator | Sep 2016 → Feb 2017 | female infertility | Bayero University Kano, Nigeria | Unknown | No outcome recorded |
| Phase 4 | NCT02689024 Comparator | May 2016 → Jul 2023 | — | Academic Medical Center - University of Amsterdam | Terminated | No outcome recorded |
| Phase 4 | NCT02400320 Background | Mar → Jun 2016 | irritant dermatitis | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 4 | NCT02406014 Comparator | Apr 2015 → Jun 2016 | actinic keratosis | LEO Pharma | Completed | No outcome recorded |
| Phase 4 | NCT03458923 Comparator | Jan 2015 → Jun 2018 | diabetic macular edema | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT02087748 Comparator | Mar → Apr 2014 | — | Lotus Clinical Research, LLC | Completed | No outcome recorded |
| Phase 4 | NCT04110587 Comparator | Dec 2013 → Jul 2019 | temporomandibular joint dysfunction syndrome | Universidad Complutense de Madrid | Completed | No outcome recorded |
| Phase 4 | NCT01453179 Comparator | Oct 2011 → Mar 2015 | actinic keratosis | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 4 | NCT01190722 Comparator | Nov → Dec 2010 | toe, misshapen | Karolinska Institutet | Withdrawn | No outcome recorded |
| Phase 4 | NCT01860833 Comparator | Apr 2010 → Aug 2011 | osteoarthritis, knee | University of Catanzaro | Completed | No outcome recorded |
| Phase 4 | NCT01067430 Comparator | Apr → Oct 2010 | rheumatoid arthritis | Northumbria Healthcare NHS Foundation Trust | Withdrawn | No outcome recorded |
| Phase 4 | NCT04819828 Background | Jan 2010 → Aug 2016 | urolithiasis | Hospital Regional de Alta Especialidad del Bajio | Completed | No outcome recorded |
| Phase 4 | NCT00954785 Comparator | Nov 2009 → Dec 2010 | — | University of Cape Town | Withdrawn | No outcome recorded |
| Phase 4 | NCT00894790 Comparator | Nov 2009 → Jan 2010 | — | Viatris Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00935116 Comparator | Jul 2009 → Sep 2010 | — | Hospital Padre Hurtado | Unknown | No outcome recorded |
| Phase 4 | NCT05829707 Comparator | Jan 2009 → Dec 2012 | chronic pain syndrome, female breast carcinoma | Osijek University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00777127 Comparator | Dec 2008 → Nov 2012 | actinic keratosis | MEDA Pharma GmbH & Co. KG | Completed | No outcome recorded |
| Phase 4 | NCT00766402 Comparator | Sep 2008 → Feb 2009 | ankylosing spondylitis | Johnson & Johnson Taiwan Ltd | Terminated | No outcome recorded |
| Phase 4 | NCT00715091 Comparator | Sep 2008 → Dec 2013 | ankylosing spondylitis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 4 | NCT00801528 Comparator | Apr → Dec 2008 | — | Meir Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00595543 Comparator | Jan 2008 → Mar 2009 | cystoid macular edema | Bp Consulting, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00800527 Comparator | Nov 2007 → Jun 2008 | — | Usak State Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00447759 Comparator | Jun 2007 → Aug 2015 | osteoarthritis, rheumatoid arthritis | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT01120015 Background | Jan 2007 → Jun 2008 | osteoarthritis, knee | Government Medical College, Amritsar | Completed | No outcome recorded |
| Phase 4 | NCT00428025 Comparator | Oct 2006 → Oct 2008 | pancreatitis | Queen's University | Terminated | No outcome recorded |
| Phase 4 | NCT01458600 Comparator | Sep 2006 → Feb 2016 | Graves disease | Mikael Lantz | Completed | No outcome recorded |
| Phase 4 | NCT00247052 Comparator | Mar 2006 → Dec 2008 | pericardial effusion | French Cardiology Society | Completed | No outcome recorded |
| Phase 4 | NCT00141102 Comparator | Oct 2005 → May 2009 | osteoarthritis, rheumatoid arthritis | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00204542 Comparator | Jun 2005 → Mar 2009 | photosensitivity disease | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 4 | NCT00650598 Comparator | Mar → Aug 2004 | neuropathy, painful | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00640432 Comparator | Oct 2003 → Oct 2004 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00671320 Comparator | Dec 2002 → Oct 2003 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00649610 Comparator | Nov 2002 → May 2003 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02528201 Comparator | Sep 2002 → Nov 2004 | ankylosing spondylitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02229747 Comparator | Aug 2001 → Feb 2002 | pharyngitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT02183129 Comparator | Apr → Nov 1999 | osteoarthritis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00568217 Comparator | Sep 1997 → Aug 2005 | — | University of Oulu | Completed | No outcome recorded |
| Phase not applicable69 trials | ||||||
| — | NCT06942702 Comparator | May → Aug 2026 overdue | — | Mersin University | Not yet recruiting | No outcome recorded |
| — | NCT07493226 Comparator | Apr 2026 → Feb 2027 expected | frozen shoulder, neuropathy, painful | Konya Beyhekim Training and Research Hospital | Recruiting | No outcome recorded |
| — | NCT07598994 Comparator | Aug 2025 → Apr 2026 | temporomandibular joint disorder | Istanbul University | Completed | No outcome recorded |
| — | NCT07071012 Comparator | Aug 2025 → Feb 2026 | — | Hacettepe University | Completed | No outcome recorded |
| — | NCT07178639 Comparator | Aug 2025 → Feb 2026 overdue | cataract, cystoid macular edema | Nemocnice Kolín | Recruiting | No outcome recorded |
| — | NCT07131527 Comparator | Jul 2025 → Jan 2026 | cholecystitis | Sohag University | Completed | No outcome recorded |
| — | NCT07117318 Background | Jul 2025 → Dec 2026 expected | acute pancreatitis | Air Force Military Medical University, China | Recruiting | No outcome recorded |
| — | NCT06298383 Comparator | Jun 2025 → Feb 2026 | pulpitis | Cairo University | Completed | No outcome recorded |
| — | NCT07071441 Comparator | Jun 2025 → Dec 2026 expected | pancreatitis | Air Force Military Medical University, China | Recruiting | No outcome recorded |
| — | NCT06976151 Background | May → Nov 2025 | autoimmune disease | Cairo University | Completed | No outcome recorded |
| — | NCT07002788 Comparator | Dec 2024 → Dec 2025 overdue | lung adenocarcinoma | Hacettepe University | Active not recruiting | No outcome recorded |
| — | NCT06602167 Background | Oct 2024 → Jul 2027 expected | breast cancer, digestive system cancer, hand-foot syndrome | Affiliated Hospital of Qinghai University | Recruiting | No outcome recorded |
| — | NCT07534969 Comparator | Sep 2024 → Mar 2026 | — | Yael Yagur | Completed | No outcome recorded |
| — | NCT06566794 Comparator | Aug 2024 → Jan 2025 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT06276231 Background | Jul 2024 → Mar 2026 | urinary tract obstruction | Oman Medical Speciality Board | Unknown | No outcome recorded |
| — | NCT07500454 Comparator | Jun → Jul 2024 | — | ISSSTE Hospital Regional "Gral. Ignacio Zaragoza" | Completed | No outcome recorded |
| — | NCT06857110 Comparator | Jun 2024 → Mar 2025 overdue | — | Hospital Universitario San Ignacio | Recruiting | No outcome recorded |
| — | NCT07613346 Comparator | Jun 2024 → Jun 2026 overdue | congenital patella dislocation, unilateral | Peking University Third Hospital | Active not recruiting | No outcome recorded |
| — | NCT06342648 Comparator | May → Oct 2024 | urinary tract obstruction | Suez Canal University | Unknown | No outcome recorded |
| — | NCT06864078 Comparator | Sep 2023 → Aug 2024 | uterine inflammatory disease | Al-Azhar University | Completed | No outcome recorded |
| — | NCT04874675 Comparator | Mar → Dec 2023 | impacted teeth, multiple | University of Zimbabwe | Suspended | No outcome recorded |
| — | NCT05507554 Comparator | Aug → Oct 2022 | ureterolithiasis | Pakistan Kidney and Liver Institute and Research Center | Unknown | No outcome recorded |
| — | NCT06630520 Background | Mar → Jun 2022 | — | Taipei Veterans General Hospital, Taiwan | Completed | No outcome recorded |
| — | NCT05398874 Background | Nov 2021 → Jun 2022 | osteoarthritis, knee | Kufa University | Completed | No outcome recorded |
| — | NCT06220279 Comparator | Jun → Dec 2021 | — | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
| — | NCT04614259 Background | Nov → Dec 2020 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04539249 Comparator | Nov 2020 → Mar 2021 | — | Olakunle Ifeoluwa Makinde | Completed | No outcome recorded |
| — | NCT04402047 Comparator | Sep 2020 → Aug 2022 | osteoarthritis, hand | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Unknown | No outcome recorded |
| — | NCT04331210 Comparator | Sep 2020 → Sep 2021 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT04500509 Background | Sep 2020 → Aug 2021 | female infertility | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT04082793 Background | Jun 2020 → Mar 2021 | head and neck cancer | Asir John Samuel | Unknown | No outcome recorded |
| — | NCT06943092 Comparator | Jan → Jun 2020 | — | Federal Teaching Hospital Abakaliki | Completed | No outcome recorded |
| — | NCT04508894 Comparator | Apr 2019 → Dec 2020 | — | Minia University | Completed | No outcome recorded |
| — | NCT04296422 Comparator | Jan 2019 → Sep 2020 | premenstrual tension | Taipei City Hospital | Unknown | No outcome recorded |
| — | NCT04270968 Background | Nov 2018 → Nov 2019 | — | Qassim University | Completed | No outcome recorded |
| — | NCT04860167 Comparator | Sep 2018 → Sep 2019 | gallbladder disorder | Institute of Liver and Biliary Sciences, India | Completed | No outcome recorded |
| — | NCT03881319 Comparator | Jun 2018 → Dec 2019 | dysmenorrhea, premenstrual tension | Taipei City Hospital | Unknown | No outcome recorded |
| — | NCT03528824 Comparator | Jun 2018 → Aug 2020 | osteoarthritis, knee | University of Duisburg-Essen | Completed | No outcome recorded |
| — | NCT03413163 Background | Feb → Apr 2018 | — | Maltepe University | Completed | No outcome recorded |
| — | NCT03298646 Comparator | Oct → Dec 2017 | — | Ain Shams University | Unknown | No outcome recorded |
| — | NCT03081728 Background | Apr → Nov 2017 | respiratory failure | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| — | NCT03020368 Comparator | Jan 2017 → Dec 2018 | — | Charite University, Berlin, Germany | Terminated | No outcome recorded |
| — | NCT03520595 Comparator | Dec 2016 → Jan 2017 | — | Tatyasaheb Kore Dental College | Completed | No outcome recorded |
| — | NCT02876432 Comparator | Oct 2016 → Jan 2017 | — | Universidad Autónoma Benito Juárez de Oaxaca | Completed | No outcome recorded |
| — | NCT02837770 Comparator | Jul 2016 → Jan 2017 | — | University Hospital of Patras | Completed | No outcome recorded |
| — | NCT02674191 Background | May 2016 → Jun 2018 | — | Manal El Namrawy | Unknown | No outcome recorded |
| — | NCT03996564 Comparator | Feb → Dec 2016 | — | San Antonio Military Medical Center | Completed | No outcome recorded |
| — | NCT02663050 Comparator | Feb → Mar 2016 | dysmenorrhea | University of Health Sciences Gulhane Faculty of Medicine | Unknown | No outcome recorded |
| — | NCT02384928 Comparator | Sep 2015 → Jan 2017 | lumbar disk disease, sciatica | Jaseng Medical Foundation | Completed | No outcome recorded |
| — | NCT02698306 Comparator | Feb 2015 → Mar 2016 | impacted teeth, multiple | Hospital Geral de Vila Penteado | Unknown | No outcome recorded |
| — | NCT03449940 Comparator | Jan 2015 → Jan 2017 | erectile dysfunction | Ministry of Health, Jamaica | Completed | No outcome recorded |
| — | NCT02132416 Comparator | May 2014 → Jun 2017 | — | Sahlgrenska University Hospital | Completed | No outcome recorded |
| — | NCT02094807 Background | Apr 2014 → May 2020 | — | Sahlgrenska University Hospital | Withdrawn | No outcome recorded |
| — | NCT02027792 Comparator | Jan → Aug 2014 | osteoarthritis, knee | University of Duisburg-Essen | Completed | No outcome recorded |
| — | NCT02007161 Comparator | Dec 2013 → Dec 2014 | — | KU Leuven | Unknown | No outcome recorded |
| — | NCT01943435 Comparator | Nov 2013 → Jun 2016 | lumbar spinal stenosis | Michael Schneider, DC, PhD | Completed | No outcome recorded |
| — | NCT01734954 Background | Apr → Aug 2013 | — | CES University | Unknown | No outcome recorded |
| — | NCT01993589 Comparator | Nov 2012 → Nov 2013 | — | Kayseri Education and Research Hospital | Completed | No outcome recorded |
| — | NCT01638962 Comparator | Aug 2012 → Aug 2015 | osteoarthritis, knee | University of Southern Denmark | Completed | No outcome recorded |
| — | NCT01350622 Comparator | Dec 2011 → Dec 2012 | — | University of Utah | Withdrawn | No outcome recorded |
| — | NCT01508676 Comparator | Nov 2011 → Mar 2013 | complex regional pain syndrome type 1, postherpetic neuralgia | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01891435 Comparator | Jan 2010 → Dec 2011 | — | Hamad Medical Corporation | Completed | No outcome recorded |
| — | NCT03362216 Comparator | Apr → May 2009 | — | Peking University People's Hospital | Completed | No outcome recorded |
| — | NCT01055470 Comparator | Dec 2008 → Jun 2009 | osteoarthritis, knee | Government Medical College, Bhavnagar | Completed | No outcome recorded |
| — | NCT00619034 Comparator | Sep 2007 → Dec 2010 | diabetic retinopathy | University of Aarhus | Completed | No outcome recorded |
| — | NCT01547559 Background | Jun 2007 → Nov 2014 | drug allergy | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT01541137 Comparator | Mar 2004 → Sep 2008 | — | Helsinki University Central Hospital | Completed | No outcome recorded |
| — | NCT00825864 Comparator | Jan 2004 → Jan 2008 | cataract, glaucoma | Sheba Medical Center | Completed | No outcome recorded |
| — | NCT02556970 Background | ? → Sep 2015 | — | University Hospitals Bristol and Weston NHS Foundation Trust | Withdrawn | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-03-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of an Authorized Generic of Flector® Patch (diclofenac epolamine topical patch) in the United States tevapharm.com ↗ |
| 2000-02-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Pharmaceutical Industries Ltd. to Launch Generic Equivalent of Voltaren XR Immediately tevapharm.com ↗ |
Evidence & citations 62 cited values
Every value below carries the sentence it was read from. 446 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diclofenac | “This study evaluated the proarrhythmic potential of hydroxypropyl-β-cyclodextrin (HPβCD)-diclofenac, a novel injectable diclofenac formulation solubilized with...” PMID 23578606 ↗ Apr 2013356“Patients will use the preservative-free dexamethasone 0.1% 4 times a day in the first week after cataract surgery, 3 times a day in the second week, twice daily in the third...” NCT04050644 ↗ “(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has...” NCT05641246 ↗ “An Evaluator-blinded, Randomized Within-subject Repeat Insult Study to Evaluate Potential Skin Irritation and Sensitization of HP-5000 (Diclofenac Sodium Topical System) in...” NCT04882319 ↗ “Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)” NCT04067492 ↗ “Purpose: This is a randomized clinical trial comparing the effects of three different medications for acute low back pain (LBP):Ketorolac, Ibuprofen, Diclofenac” NCT03861611 ↗ “Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg” NCT01734954 ↗ “Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months” NCT04091022 ↗ “Diclofenac sodium gel in 3 different concentrations as- Diclofenac sodium 1%, 1.16% and 2.32% whichever was available in the given region.” NCT06379893 ↗ “The participants will receive non-steroidal anti- inflammatory drugs (NSAID), Diclofenac 20 mg/ day for 3 consecutive menstrual cycles.” NCT06976151 ↗ “Drug: intra muscular injection Diclofenac Sodium 50 mg and then oral Tablet Diclofenac Sodium 50 mg, once patient starts taking orally.” NCT05507554 ↗ “diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.” NCT03409874 ↗ “The purpose of this study is to see if the drug Pennsaid (Diclofenac) can help reduce pain felt by people with chronic nerve pain.” NCT01508676 ↗ “All patients without contraindications should receive 100mg rectal indomethacin or diclofenac within 30mins before ERCP procedure” NCT07117318 ↗ “Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.” NCT01421433 ↗ “Patients randomized into this group (n=40) will, again by simple randomization, be given oral tablets of etodolac or diclofenac” NCT07493226 ↗ “A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control” NCT01211431 ↗ “Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days” NCT01205477 ↗ “Oral acetaminophen (1 g) and diclofenac (50 mg) administered during the first 24 hours postpartum together every 8 houers” NCT07534969 ↗ “Patients with AS were randomised for treatment with either continuous (150 mg/day) or on-demand diclofenac for 2 years.” PMID 26242443 ↗ Aug 2015 “diclofenac 50 mg twice a day, prednisone 5mg once daily, methotrexate 10mg once weekly or sulfasalazine 500 twice daily” NCT06594822 ↗ “G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.” NCT00935116 ↗ “a product containing the non-steroidal anti-inflammatory drug diclofenac (Voltaren) on trapezius trigger point pain.” NCT03939884 ↗ “IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.” NCT02674386 ↗ “patients will be randomized to either receive an unmarked suppository of Diclofenac or a placebo suppository.” NCT01542567 ↗ “IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study” NCT03031938 ↗ “Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks” NCT02528188 ↗ “GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.” NCT01547559 ↗ “All patients had oral paracetamol 500mg, 4 times/day and diclofenac 75mg, 1 times/day after surgery.” NCT06630520 ↗ “Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia” NCT05322603 ↗ “Diclofenac is one of potent, standard and most unique NSAID for the therapy of postoperative pain.” NCT03520595 ↗ “NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam. Oral contraceptives include Yasmin.” NCT03881319 ↗ “Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months.” NCT01120015 ↗ “Diclofenac Na 0.1% Oph Soln, "Dicloftil®", NSAID eyedrops administered three days before surgery” NCT03597867 ↗ “2. Diclofenac 75 milligram (mg) twice per day from postoperative day 7 to postoperative day 14.” NCT06561035 ↗ “participants received 1% topical diclofenac gel on the tender points 3 times /day for 4 weeks.” NCT04270968 ↗ “IM diclofenac sodium (75 mg amp) (Voltaren, Novartis Pharmaceuticals Corporation, Switzerland)” NCT04508894 ↗ “Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.” NCT02400320 ↗ “the amount of the drug diclofenac which penetrates (enters) the fatty tissue under the skin” NCT01592019 ↗ “all patients were received intraoperative diclofenac sodium 0.5 mg/kg intramuscular” NCT04614259 ↗ “with Group A receiving additional Phonophoresis using ultrasound and diclofenac gel” NCT06439251 ↗ “gastric/duodenal risk only: diclofenac, 50-100 mg per intake, plus lansoprazole” NCT05761015 ↗ “Voltaren® Schmerzgel forte; 2.32% containing 2.32% Diclofenac-N-Ethylethanamin.” NCT06954181 ↗ “After 12, 24 and 48 hours from patient arrival: TAB. Diclofenac 100 milligrams.” NCT01764048 ↗ “oral Voltaren sustained-release tablets (diclofenac) at 0.5 mg/kg twice daily.” NCT07613346 ↗ “including oral celecoxib, topical diclofenac, and other skin protectants” NCT06602167 ↗ “* Diclofenac - 2 to 3 mg/kg/day in divided doses 2 to 3 times daily” NCT05871086 ↗ “preservative-free dexamethasone (DEX), diclofenac (DICLO) eye drops” PMID 36602718 ↗ Jan 2023 “NSAIDs include Ibuprofen, Naproxen, Diclofenac, and Piroxicam.” NCT04296422 ↗ “Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).” NCT04110587 ↗ “Topical gel containing lidocaine (2%) plus diclofenac (0.5%)” NCT02961855 ↗ “Ultrasound (BM1-1039) Ultrasonic massage with Diclofenac gel” NCT04082793 ↗ “NSAIDs: ibuprofen, celecoxib, or diclofenac/misoprostol” NCT01943435 ↗ “intravenous diclofenac 75 mg twice daily will be added.” NCT04657952 ↗ “Rectal diclofenac 100mg and misoprostol 400mcg stat” NCT03518463 ↗ “transdermal diclofenac patch - 200mg for group B” NCT06146491 ↗ “Topical diclofenac emulgel (Voltaren) 11.6 mg/g.” NCT07145645 ↗ “Medications: Ibuprofen, Naproxen, or Diclofenac.” NCT06453291 ↗ “Intramuscular diclofenac will be administered” NCT03413163 ↗ “75 mg of Diclofenac intramuscular Injection” NCT06276231 ↗ “100 mg of suppository diclofenac 12 hourly” NCT04539249 ↗ “Diclofenac 75mg c 12h Tramadol 50mg c 12h.” NCT03380533 ↗ “diclofenac sodium (Drug class: NSAIDs)” NCT02384928 ↗ “NSAIDs (e.g., Ibuprofen, Diclofenac)” NCT07016451 ↗ “75 mg (3ml) intramuscular Diclofenac” NCT04849468 ↗ “Diclofenac gel on the target knee” NCT03691844 ↗ “diclofenac (Diclobene) 100mg” NCT06710600 ↗ “Eye drops diclofenac 1mg/ml” NCT02059018 ↗ “Diclofenac 3% - an NSAID.” NCT02485145 ↗ “Diclofenac 5%” NCT00530387 ↗ “Diclofenac” NCT01638962 ↗ “Diclofenac” NCT02094807 ↗ “Diclofenac” NCT02132416 ↗ |
| Known as | AMZ001 | “AMZ001 (Diclofenac Sodium Gel 3.06%)” NCT05968482 ↗1“AMZ001 Diclofenac gel” NCT06693648 ↗ |
| Known as | Cataflam | “Diclofenac group, which received diclofenac 50 mg capsules (Cataflam) and placebo sprays.” NCT03745599 ↗ |
| Known as | DCS | “Diclofenac Sodium (DCS)” NCT07506265 ↗1“Diclofenac Sodium (DCS)” NCT06632015 ↗ |
| Known as | DF-ME | “DF-ME, which consists of 2% diclofenac sodium, was compounded according to the published instructions by RS Therapeutics Inc. (Canada) and stored in the same containers as SHT-ME.” NCT06184685 ↗ |
| Known as | DIC075V | “intravenous diclofenac sodium (DIC075V) in adult volunteers” NCT00509743 ↗3“Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels” NCT00448110 ↗ “Intravenous diclofenac sodium (DIC075V) 18.75 mg” NCT00474136 ↗ “intravenous diclofenac sodium (DIC075V)” NCT00548678 ↗ |
| Known as | DICL-SR | “with Diclofenac Sodium Sustained Release Tablets (DICL-SR) 75mg, quaque die(QD)” NCT02826031 ↗ |
| Known as | DICLO | “preservative-free dexamethasone (DEX), diclofenac (DICLO) eye drops” PMID 36602718 ↗ Jan 2023 |
| Known as | Dicloabak | “Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye...” NCT04050644 ↗ |
| Known as | Diclobene | “diclofenac (Diclobene) 100mg” NCT06710600 ↗ |
| Known as | Diclofenac 50 mg oral tablet | “Diclofenac 50 mg oral tablet” NCT03506763 ↗ |
| Known as | Diclofenac diethylamine 1.16% gel | “Drug: Diclofenac diethylamine 1.16% gel” NCT06729073 ↗ |
| Known as | Diclofenac epolamine | “A topical formulation of diclofenac (FLECTOR diclofenac epolamine topical system (FDETS)) is approved in adults for the treatment of acute pain due to minor strains, sprains,...” PMID 34826122 ↗ Nov 20212“Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day” NCT04976088 ↗ “FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%” NCT01054820 ↗ |
| Known as | Diclofenac Epolamine Patch | “Drug: Diclofenac Epolamine Patch” NCT03145259 ↗ |
| Known as | Diclofenac hydroxyethylpyrrolidine | “Drug: Diclofenac hydroxyethylpyrrolidine” NCT01946984 ↗ |
| Known as | Diclofenac Microemulsion | “Drug: Diclofenac Microemulsion” NCT06184685 ↗ |
| Known as | Diclofenac Na | “Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.” NCT00476593 ↗1“Diclofenac Na gel” NCT00601640 ↗ |
| Known as | Diclofenac Na 0.1% Oph Soln | “Diclofenac Na 0.1% Oph Soln” NCT03597867 ↗ |
| Known as | diclofenac potassium | “BACKGROUND: Diclofenac potassium for oral solution (CAMBIA®) may be an alternative for patients who would otherwise need to be seen in a healthcare setting for parenteral ketorolac.” PMID 31833000 ↗ Dec 201918“The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours.” NCT06752486 ↗ “NSAIDs, Diclofenac Potassium in this study, is known as a drug which is effective for pain control and is as effective as coxib in acute pain management.” NCT01762306 ↗ “The tablets being tested will contain the drug, diclofenac potassium.” NCT02004301 ↗ “preoperative Diclofenac Potassium (50 mg Cataflam)” NCT03174860 ↗ “Diclofenac Potassium for Oral Solution 50 mg” NCT02287376 ↗ “Oral diclofenac potassium 50 mg” NCT00474136 ↗ “Drug: Diclofenac Potassium” NCT02255045 ↗ “Drug: Diclofenac potassium” NCT02476422 ↗ |
| Known as | Diclofenac Sodium | “In a randomized, double-blind, placebo-controlled trial, men and women aged > or = 40 years diagnosed with primary OA in the dominant hand were randomly assigned to self-apply...” PMID 19648310 ↗ Jul 200989“A Randomized, Double-blind, Multi-site, Comparator-controlled, Phase III Trial to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Tramadol Hydrochloride and...” NCT03714672 ↗ “Diclofenac sodium gel (DSG) is one of the commonly used topical NSAIDs, which can provide local pain relief for patients with hand OA with reduced systemic exposure,...” NCT04402047 ↗ “From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks...” NCT02306031 ↗ “The objective of this study was to investigate the efficacy and safety of diclofenac sodium 2% topical solution BID versus vehicle control solution for treating pain associated...” PMID 26506138 ↗ Nov 2015 “An Evaluator-blinded, Randomized Within-subject Repeat Insult Study to Evaluate Potential Skin Irritation and Sensitization of HP-5000 (Diclofenac Sodium Topical System) in...” NCT04882319 ↗ “Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain.” NCT00640939 ↗ “Cerimon Pharmaceuticals is investigating a topical patch formulation of diclofenac sodium containing 15 mg of diclofenac sodium for the local treatment of acute musculoskeletal pain.” NCT00640705 ↗ “OBJECTIVE: To evaluate the safety and efficacy of topical diclofenac sodium 1% gel (DSG) versus vehicle in patients aged 25-64 or ≥65 years who have been diagnosed with knee OA.” PMID 21174485 ↗ Jan 2011 “Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications” NCT04585334 ↗ “Objective: To compare the analgesic effectiveness of diclofenac sodium, bupivacaine or bupivacaine plus diclofenac sodium infiltrating wound appendectomies.” NCT02752971 ↗ “A single oral dose of 100 mg diclofenac sodium will be administered to participants in the Diclofenac Sodium Group prior to the endodontic procedure.” NCT06937853 ↗ “Patients received 75 mg of inj. Diclofenac sodium (diluted in 100 ml of 0.9 % normal saline) intravenously 30 mins before the start of procedure” NCT04860167 ↗ “Diclofenac sodium gel in 3 different concentrations as- Diclofenac sodium 1%, 1.16% and 2.32% whichever was available in the given region.” NCT06379893 ↗ “Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%” NCT00595543 ↗ “Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.” NCT05188131 ↗ “To demonstrate the relative bioavailability of Diclofenac Sodium 75 mg enteric-coated tablets under non-fasting conditions.” NCT00913887 ↗ “Patients will receive approximately 2 h prior to the procedure 1 tablet of diclofenac sodium 50 mg and 1 tablet of placebo.” NCT03506763 ↗ “0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly will perform for postoperative analgesia.” NCT04148729 ↗ “Daily Application antifungal gel of miconazole 3% and diclofenac sodium 1% and urea 40% to infected nails.” NCT04341402 ↗ “Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.” NCT00594854 ↗ “injectable diclofenac sodium, Dyloject®, is solubilized with hydroxypropyl β-cyclodextrin (HPβCD)” PMID 22886837 ↗ Aug 2012 “IM diclofenac sodium (75 mg amp) (Voltaren, Novartis Pharmaceuticals Corporation, Switzerland)” NCT04508894 ↗ “Test product: Diclofenac Sodium 140 mg medicated plaster, topical application once a day” NCT04976088 ↗ “diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days” NCT00650598 ↗ “with Diclofenac Sodium Sustained Release Tablets (DICL-SR) 75mg, quaque die(QD)” NCT02826031 ↗ “the sixth group consisted of 25 participants receiving diclofenac sodium” NCT01993589 ↗ “diclofenac sodium topical solution, diclofenac topical solution 1.5%” NCT03471507 ↗ “Amoxicillin 500 mg, Metronidazole 500 mg, Diclofenac sodium 50 mg” NCT07304882 ↗ “Diclofenac sodium topical gel 1% (Anchen Pharmaceuticals, Inc.)” NCT01456611 ↗ “Give antibiotics or diclofenac sodium suppository as needed.” NCT06105827 ↗ “intravenous diclofenac sodium (DIC075V) in adult volunteers” NCT00509743 ↗ “Solaraze® (Diclofenac sodium) 2x/day topical for 3 months” NCT00204542 ↗ “Diclofenac Sodium 50 mg associated with Codeine 50 mg” NCT02665533 ↗ “Diclofenac sodium gel, 3% is an FDA-approved drug.” NCT02952898 ↗ “Intravenous diclofenac sodium (DIC075V) 18.75 mg” NCT00474136 ↗ “Diclofenac Sodium Active Topical Patch 1” NCT03277066 ↗ “intravenous diclofenac sodium (DIC075V)” NCT00548678 ↗ “DIC075V (intravenous diclofenac sodium)” NCT00726388 ↗ “topical diclofenac sodium 1% gel (DSG)” PMID 22030938 ↗ Sep 2011 “diclofenac sodium (Drug class: NSAIDs)” NCT02384928 ↗ “AMZ001 (Diclofenac Sodium Gel 3.06%)” NCT05968482 ↗ “Drug: diclofenac sodium (cataflam)” NCT02714231 ↗ “Diclofenac Sodium Topical Gel, 1%” NCT02121002 ↗ “Diclofenac sodium topical gel 1%” NCT01272947 ↗ “topical diclofenac sodium gel” NCT00601640 ↗ “diclofenac sodium (25mg/ml)” NCT06186921 ↗ “Diclofenac Sodium gel, 1%” NCT02596451 ↗ “Diclofenac sodium gel 1%” NCT00171652 ↗ “Drug: Diclofenac Sodium” NCT07131527 ↗ “Drug: Diclofenac Sodium” NCT03221946 ↗ “Drug: Diclofenac Sodium” NCT05626140 ↗ “Diclofenac Sodium Patch” NCT00931866 ↗ |
| Known as | Diclofenac sodium gel | “Drug: Diclofenac sodium gel” NCT06729073 ↗ |
| Known as | diclofenac sodium solution | “Drug: diclofenac sodium solution” NCT03145259 ↗ |
| Known as | diclofenac-cholestyramine | “continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily” NCT00715091 ↗ |
| Known as | Dicloftil | “Diclofenac Na 0.1% Oph Soln, "Dicloftil®", NSAID eyedrops administered three days before surgery” NCT03597867 ↗ |
| Known as | Diclophenac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00893854 ↗ |
| Known as | Diclophenac Potassium | “Diclophenac Potassium” NCT02663050 ↗ |
| Known as | diclophenac sodium | “Patients will be given 100mg p.o. diclophenac sodium tablets” NCT02339428 ↗ |
| Known as | DIEP | “Reference product: Active-comparator, Diclofenac epolamine (DIEP) 180 mg medicated plaster, Flector®, topical application once a day” NCT04976088 ↗ |
| Known as | Diklofenak | “Preservative free Diklofenak 1mg/mL drops (Voltaren minims) four times a day from three days before surgery.” NCT05433428 ↗ |
| Known as | Diklofenak Sodyum | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07002788 ↗ |
| Known as | DIV075V | “Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery” NCT00507026 ↗ |
| Known as | DPSGC | “Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC; Zipsor*) is a novel formulation of diclofenac potassium used to treat mild to moderate acute pain.” PMID 22587481 ↗ Jun 20121“Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) is a rapid” PMID 19922878 ↗ Oct 2009 |
| Known as | drug: diclofenac sodium | “drug: diclofenac sodium” NCT04341402 ↗ |
| Known as | DSG | “The purpose of this study is to evaluate the efficacy of Diclofenac Sodium Topical (DSG) 1% compared with placebo applied four times a day in subjects with acute ankle sprains...” NCT01255423 ↗5“Diclofenac sodium gel (DSG) is one of the commonly used topical NSAIDs, which can provide local pain relief for patients with hand OA with reduced systemic exposure,...” NCT04402047 ↗ “OBJECTIVE: To evaluate the safety and efficacy of topical diclofenac sodium 1% gel (DSG) versus vehicle in patients aged 25-64 or ≥65 years who have been diagnosed with knee OA.” PMID 21174485 ↗ Jan 2011 “Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness (DOMS) of the Lower Limbs” NCT02271854 ↗ “Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily” NCT01272934 ↗ “topical diclofenac sodium 1% gel (DSG)” PMID 22030938 ↗ Sep 2011 |
| Known as | Dyloject | “injectable diclofenac sodium, Dyloject®, is solubilized with hydroxypropyl β-cyclodextrin (HPβCD)” PMID 22886837 ↗ Aug 2012 |
| Known as | FDETS | “A topical formulation of diclofenac (FLECTOR diclofenac epolamine topical system (FDETS)) is approved in adults for the treatment of acute pain due to minor strains, sprains,...” PMID 34826122 ↗ Nov 2021 |
| Known as | FLECTOR | “FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%” NCT01054820 ↗ |
| Known as | HP-5000 | “An Evaluator-blinded, Randomized Within-subject Repeat Insult Study to Evaluate Potential Skin Irritation and Sensitization of HP-5000 (Diclofenac Sodium Topical System) in...” NCT04882319 ↗ |
| Known as | HPβCD-diclofenac | “This study evaluated the proarrhythmic potential of hydroxypropyl-β-cyclodextrin (HPβCD)-diclofenac, a novel injectable diclofenac formulation solubilized with...” PMID 23578606 ↗ Apr 20131“Hydroxypropyl-β-cyclodextrin-diclofenac (HPβCD-diclofenac) is an NSAID used to treat acute moderate-to-severe postoperative pain.” PMID 29492863 ↗ Mar 2018 |
| Known as | Hydroxypropyl-β-cyclodextrin-diclofenac | “Hydroxypropyl-β-cyclodextrin-diclofenac (HPβCD-diclofenac) is an NSAID used to treat acute moderate-to-severe postoperative pain.” PMID 29492863 ↗ Mar 2018 |
| Known as | Itami | “Diclofenac sodium 140 mg medicated plaster (Itami®) will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications” NCT04585334 ↗ |
| Known as | LAS41007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01265602 ↗ |
| Known as | Licart | “The Licart™ (diclofenac epolamine) topical system was designed to deliver the nonsteroidal anti-inflammatory drug (NSAID) diclofenac to the site of a minor soft tissue injury...” NCT05171673 ↗ |
| Known as | Pennsaid | “Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis” NCT01579890 ↗ |
| Known as | PENNSAID Gel | “PENNSAID Gel is a new topical gel formulation of diclofenac sodium that is similar in composition to PENNSAID solution.” NCT01202799 ↗ |
| Known as | Sodium diclofenac | “Drug: Sodium diclofenac” NCT02752971 ↗ |
| Known as | Solaraze | “To compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Actavis) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera...” NCT01962987 ↗6“Solaraze-topical diclofenac 3% and Vaniqa-topical eflornithine hydrochloride Cream, 13.9% applied to bilateral arms for a period of 9 months” NCT04091022 ↗ “using Aldara® 5% cream (Imiquimod) or Solaraze® 3% gel (Diclofenac) on the face or the scalp” NCT01453179 ↗ “Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.” NCT01742663 ↗ “Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharmaceuticals Inc.)” NCT03826550 ↗ “Solaraze® (Diclofenac sodium) 2x/day topical for 3 months” NCT00204542 ↗ |
| Known as | SoluMatrix Diclofenac | “Low-dose SoluMatrix® diclofenac has been developed to provide efficacy at lower diclofenac doses.” PMID 25913498 ↗ Apr 20151“SoluMatrix® Diclofenac: Sustained Opioid-Sparing Effects in a Phase 3 Study” PMID 26995799 ↗ Mar 2016 |
| Known as | TDS-943 | “TDS-943 (topical diclofenac sodium 4% spray)” NCT00546832 ↗ |
| Known as | Voltaren | “A Multi-Center, Double-Blind, Vehicle-Controlled, Parallel-Group Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%...” NCT02121002 ↗19“Voltaren®, 50 mg soluble tablets, was selected among other possible diclofenac products because with this formulation peak concentration of diclofenamic acid is achieved at...” NCT02495831 ↗ “(VOLTAREN®) Emulgel 1% contain the active ingredient diclofenac which belongs to the NSAIDS.it has analgesic and anti-inflammatory properties and due to its alcohol base it has...” NCT05641246 ↗ “Voltaren® (diclofenac) orally with water at the dose 50 mg thrice daily for 3 days (150 mg total daily dose), then 25 mg thrice daily for 9 days (75 mg total daily dose)” NCT04067492 ↗ “a product containing the non-steroidal anti-inflammatory drug diclofenac (Voltaren) on trapezius trigger point pain.” NCT03939884 ↗ “Diclofenac sodium: 1 mL of gel prepared by incorporating 1 mL of 3 mL/75 mg Voltaren into a 1% Carbopol 940 gel base” NCT07101016 ↗ “group II who will receive diclofenac 100mg (voltaren® 100, Novartis) 1 hour before the procedure” NCT02419651 ↗ “IM diclofenac sodium (75 mg amp) (Voltaren, Novartis Pharmaceuticals Corporation, Switzerland)” NCT04508894 ↗ “Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography” NCT02433418 ↗ “oral Voltaren sustained-release tablets (diclofenac) at 0.5 mg/kg twice daily.” NCT07613346 ↗ “diclofenac 50mg (voltaren®, Novartis) 1 hour before the procedure” NCT02425709 ↗ “topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)” NCT01761071 ↗ “Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis)” NCT01456611 ↗ “Topical diclofenac emulgel (Voltaren) 11.6 mg/g.” NCT07145645 ↗ “Voltaren - Diclofenac sodium gel 1% (GSK, USA)” NCT04592016 ↗ “Voltaren” NCT02094807 ↗ |
| Known as | Voltaren (Ophta SDU;Novartis Pharms) eye drops. | “Voltaren (Ophta SDU;Novartis Pharms) eye drops.” NCT00476593 ↗ |
| Known as | voltaren 100 | “group II who will receive oral diclofenac 100mg (voltaren® 100, Novartis) 1 hour before the procedure” NCT02428777 ↗ |
| Known as | Voltaren Gel | “In a randomized, double-blind, placebo-controlled trial, men and women aged > or = 40 years diagnosed with primary OA in the dominant hand were randomly assigned to self-apply...” PMID 19648310 ↗ Jul 20091“Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%” NCT02596451 ↗ |
| Known as | Voltaren minims | “Preservative free Diklofenak 1mg/mL drops (Voltaren minims) four times a day from three days before surgery.” NCT05433428 ↗ |
| Known as | Voltaren Ophta SDU;Novartis Pharms | “Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.” NCT00476593 ↗ |
| Known as | Voltaren Ophtha | “Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye...” NCT04050644 ↗ |
| Known as | Voltaren or Votalin. | “Voltaren or Votalin.” NCT02087462 ↗ |
| Known as | Zipsor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01982539 ↗ |
| Action | Inhibit | “Diclophenac is a non-steroid anti-inflammatory drug that improves the vision and decreases the macular thickness by slowing down the prostaglandin E2 (PGE2) ending in vascular...” NCT00893854 ↗ |
| Modality | Other / unclassified | “Diclofenac is a non steroidal anti inflammatory drug” NCT02425709 ↗ |
| Route | Topical | “the patient will apply a topical solution to his/her osteoarthritic knee” NCT00108992 ↗ |
| Target | PPARG | “diclofenac has been shown to interact with PPAR-gamma in physiological concentrations and to antagonise PPAR-gamma mediated effects like adipogenesis” NCT01458600 ↗ |